Eric Clambey
Concepts (413)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gammaherpesvirinae | 8 | 2021 | 45 | 1.940 |
Why?
| | Herpesviridae Infections | 6 | 2021 | 150 | 1.430 |
Why?
| | CD8-Positive T-Lymphocytes | 13 | 2021 | 917 | 1.320 |
Why?
| | Gene Expression Regulation, Viral | 5 | 2021 | 94 | 1.170 |
Why?
| | T-Lymphocytes, Regulatory | 7 | 2021 | 388 | 1.080 |
Why?
| | B7-H1 Antigen | 5 | 2024 | 241 | 0.850 |
Why?
| | Receptor, Adenosine A2B | 4 | 2013 | 65 | 0.760 |
Why?
| | Immunologic Memory | 8 | 2020 | 366 | 0.730 |
Why?
| | Head and Neck Neoplasms | 7 | 2022 | 556 | 0.710 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2020 | 364 | 0.700 |
Why?
| | Virus Replication | 4 | 2021 | 529 | 0.680 |
Why?
| | RNA, Untranslated | 3 | 2021 | 123 | 0.680 |
Why?
| | Mice | 44 | 2024 | 18329 | 0.660 |
Why?
| | Virus Latency | 6 | 2021 | 90 | 0.660 |
Why?
| | Host-Pathogen Interactions | 3 | 2019 | 371 | 0.650 |
Why?
| | Flow Cytometry | 5 | 2018 | 1172 | 0.640 |
Why?
| | Lung Neoplasms | 7 | 2023 | 2637 | 0.610 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2024 | 1455 | 0.600 |
Why?
| | Virus Activation | 5 | 2021 | 95 | 0.600 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2020 | 173 | 0.590 |
Why?
| | Animals | 56 | 2024 | 38030 | 0.580 |
Why?
| | Immunomodulation | 2 | 2019 | 101 | 0.580 |
Why?
| | Ischemia | 4 | 2015 | 421 | 0.580 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2020 | 292 | 0.570 |
Why?
| | Clone Cells | 3 | 2008 | 266 | 0.530 |
Why?
| | Epigenesis, Genetic | 2 | 2020 | 684 | 0.530 |
Why?
| | Interleukin-10 | 1 | 2019 | 309 | 0.510 |
Why?
| | Tumor Microenvironment | 9 | 2021 | 732 | 0.500 |
Why?
| | Mice, Inbred C57BL | 24 | 2023 | 5988 | 0.490 |
Why?
| | Ikaros Transcription Factor | 2 | 2013 | 23 | 0.480 |
Why?
| | G(M1) Ganglioside | 1 | 2015 | 8 | 0.470 |
Why?
| | Kidney Diseases | 2 | 2020 | 425 | 0.460 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 3 | 2021 | 80 | 0.460 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 2 | 2014 | 331 | 0.450 |
Why?
| | T-Lymphocytes | 4 | 2017 | 1982 | 0.450 |
Why?
| | RNA, Viral | 1 | 2019 | 687 | 0.450 |
Why?
| | Hypoxia | 2 | 2013 | 1199 | 0.440 |
Why?
| | Diagnostic Imaging | 1 | 2018 | 338 | 0.440 |
Why?
| | Drug Resistance, Neoplasm | 4 | 2024 | 881 | 0.430 |
Why?
| | Mice, Transgenic | 10 | 2019 | 2182 | 0.420 |
Why?
| | Killer Cells, Natural | 3 | 2021 | 467 | 0.420 |
Why?
| | Antineoplastic Agents, Immunological | 4 | 2021 | 199 | 0.410 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 3 | 2023 | 235 | 0.410 |
Why?
| | Mice, Knockout | 11 | 2023 | 3119 | 0.400 |
Why?
| | Antibodies | 1 | 2015 | 401 | 0.390 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2018 | 780 | 0.390 |
Why?
| | Forkhead Transcription Factors | 2 | 2019 | 202 | 0.380 |
Why?
| | RNA, Messenger | 2 | 2019 | 2829 | 0.370 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2020 | 1217 | 0.370 |
Why?
| | Interleukin-12 | 1 | 2013 | 117 | 0.370 |
Why?
| | Cisplatin | 2 | 2024 | 334 | 0.370 |
Why?
| | Aging | 5 | 2018 | 1964 | 0.360 |
Why?
| | CD4-Positive T-Lymphocytes | 5 | 2020 | 1128 | 0.340 |
Why?
| | Gene Expression Regulation | 4 | 2015 | 2603 | 0.340 |
Why?
| | Immunotherapy | 4 | 2021 | 652 | 0.340 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2012 | 297 | 0.340 |
Why?
| | Kidney | 5 | 2023 | 1495 | 0.340 |
Why?
| | Endotoxins | 1 | 2012 | 220 | 0.340 |
Why?
| | Neutrophils | 2 | 2017 | 1134 | 0.330 |
Why?
| | Radioimmunotherapy | 2 | 2021 | 22 | 0.330 |
Why?
| | Radiation Tolerance | 3 | 2021 | 103 | 0.330 |
Why?
| | Pneumonia | 3 | 2017 | 630 | 0.310 |
Why?
| | Programmed Cell Death 1 Receptor | 4 | 2020 | 264 | 0.300 |
Why?
| | Cyclins | 2 | 2021 | 84 | 0.280 |
Why?
| | Mice, Inbred BALB C | 8 | 2021 | 1253 | 0.280 |
Why?
| | STAT3 Transcription Factor | 2 | 2020 | 207 | 0.280 |
Why?
| | Open Reading Frames | 2 | 2018 | 132 | 0.280 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 3 | 2023 | 1180 | 0.270 |
Why?
| | Interferon-gamma | 3 | 2020 | 784 | 0.270 |
Why?
| | Acute Kidney Injury | 2 | 2012 | 862 | 0.260 |
Why?
| | Signal Transduction | 6 | 2019 | 5221 | 0.260 |
Why?
| | Oxygen | 1 | 2013 | 995 | 0.260 |
Why?
| | Immunophenotyping | 2 | 2019 | 322 | 0.260 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p18 | 2 | 2018 | 15 | 0.250 |
Why?
| | Intestinal Mucosa | 1 | 2012 | 676 | 0.250 |
Why?
| | Viral Proteins | 4 | 2021 | 355 | 0.250 |
Why?
| | Inflammation | 4 | 2020 | 2877 | 0.240 |
Why?
| | Nuclear Proteins | 2 | 2021 | 748 | 0.230 |
Why?
| | Papillomavirus Infections | 2 | 2022 | 345 | 0.230 |
Why?
| | Dendritic Cells | 2 | 2021 | 499 | 0.210 |
Why?
| | Cell Line, Tumor | 9 | 2024 | 3539 | 0.210 |
Why?
| | Antigens, Viral | 2 | 2021 | 182 | 0.200 |
Why?
| | Antineoplastic Agents | 3 | 2024 | 2192 | 0.200 |
Why?
| | Disease Models, Animal | 7 | 2020 | 4556 | 0.200 |
Why?
| | Cell Proliferation | 6 | 2020 | 2494 | 0.200 |
Why?
| | Immunity, Cellular | 2 | 2019 | 272 | 0.190 |
Why?
| | Lymphocyte Depletion | 2 | 2021 | 132 | 0.190 |
Why?
| | Spleen | 2 | 2002 | 508 | 0.190 |
Why?
| | Cell Separation | 2 | 2018 | 307 | 0.190 |
Why?
| | Humans | 35 | 2024 | 144261 | 0.190 |
Why?
| | Myeloid-Derived Suppressor Cells | 2 | 2020 | 72 | 0.190 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2024 | 101 | 0.190 |
Why?
| | Peritoneal Cavity | 1 | 2002 | 30 | 0.190 |
Why?
| | Polycystic Kidney Diseases | 1 | 2023 | 71 | 0.190 |
Why?
| | Stomach Neoplasms | 1 | 2024 | 126 | 0.180 |
Why?
| | Acute Lung Injury | 2 | 2017 | 302 | 0.180 |
Why?
| | Sequence Deletion | 1 | 2002 | 193 | 0.180 |
Why?
| | Tumor Cells, Cultured | 2 | 2020 | 919 | 0.170 |
Why?
| | Lymphocytic choriomeningitis virus | 2 | 2018 | 36 | 0.170 |
Why?
| | Adaptive Immunity | 2 | 2023 | 169 | 0.170 |
Why?
| | Tryptophan | 1 | 2023 | 180 | 0.170 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 919 | 0.170 |
Why?
| | RNA Polymerase III | 1 | 2021 | 34 | 0.170 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2024 | 255 | 0.170 |
Why?
| | Immune Tolerance | 2 | 2020 | 379 | 0.160 |
Why?
| | Gamma Rays | 1 | 2020 | 56 | 0.160 |
Why?
| | Epithelial Cells | 3 | 2018 | 1125 | 0.160 |
Why?
| | Oligonucleotides, Antisense | 1 | 2020 | 114 | 0.160 |
Why?
| | Cells, Cultured | 5 | 2018 | 4146 | 0.160 |
Why?
| | Aldehyde-Lyases | 1 | 2020 | 3 | 0.160 |
Why?
| | Thymocytes | 1 | 2020 | 34 | 0.150 |
Why?
| | Splenectomy | 1 | 2020 | 65 | 0.150 |
Why?
| | Sphingosine | 1 | 2020 | 45 | 0.150 |
Why?
| | Ileitis | 1 | 2020 | 33 | 0.150 |
Why?
| | Complement Factor H | 1 | 2020 | 80 | 0.150 |
Why?
| | Lysophospholipids | 1 | 2020 | 77 | 0.150 |
Why?
| | Discoidin Domain Receptor 2 | 1 | 2019 | 6 | 0.150 |
Why?
| | Receptor, EphB4 | 1 | 2019 | 33 | 0.150 |
Why?
| | Ephrin-B2 | 1 | 2019 | 45 | 0.150 |
Why?
| | Cell Line | 7 | 2018 | 2879 | 0.140 |
Why?
| | Promoter Regions, Genetic | 2 | 2021 | 1255 | 0.140 |
Why?
| | Lymphocytic Choriomeningitis | 1 | 2018 | 25 | 0.140 |
Why?
| | Dasatinib | 1 | 2019 | 57 | 0.140 |
Why?
| | Radiosurgery | 1 | 2022 | 400 | 0.140 |
Why?
| | Lymph Nodes | 2 | 2018 | 502 | 0.140 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2018 | 29 | 0.140 |
Why?
| | Genes, Reporter | 1 | 2019 | 275 | 0.140 |
Why?
| | Varicellovirus | 1 | 2018 | 17 | 0.140 |
Why?
| | Neoplasms, Experimental | 1 | 2019 | 173 | 0.140 |
Why?
| | Monkey Diseases | 1 | 2018 | 25 | 0.140 |
Why?
| | Trans-Activators | 1 | 2020 | 405 | 0.130 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 442 | 0.130 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 154 | 0.130 |
Why?
| | Receptors, Complement | 1 | 2017 | 125 | 0.130 |
Why?
| | Transplantation Tolerance | 1 | 2017 | 37 | 0.130 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2020 | 291 | 0.130 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2020 | 370 | 0.120 |
Why?
| | Islets of Langerhans Transplantation | 1 | 2017 | 67 | 0.120 |
Why?
| | T-Lymphocyte Subsets | 2 | 2009 | 415 | 0.120 |
Why?
| | Green Fluorescent Proteins | 1 | 2018 | 405 | 0.120 |
Why?
| | Chemokines, CXC | 1 | 2016 | 68 | 0.120 |
Why?
| | Down-Regulation | 2 | 2016 | 627 | 0.120 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 474 | 0.120 |
Why?
| | Crohn Disease | 1 | 2020 | 260 | 0.120 |
Why?
| | Blood Substitutes | 1 | 1996 | 28 | 0.120 |
Why?
| | Cytokines | 3 | 2020 | 2061 | 0.120 |
Why?
| | Cytotoxicity, Immunologic | 4 | 2019 | 223 | 0.120 |
Why?
| | Mice, 129 Strain | 2 | 2013 | 86 | 0.120 |
Why?
| | Antigen Presentation | 1 | 2017 | 205 | 0.120 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2021 | 641 | 0.120 |
Why?
| | Immune Evasion | 1 | 2016 | 64 | 0.120 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2015 | 41 | 0.110 |
Why?
| | Papillomaviridae | 1 | 2016 | 115 | 0.110 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2015 | 69 | 0.110 |
Why?
| | Drug Delivery Systems | 1 | 2019 | 379 | 0.110 |
Why?
| | Rhadinovirus | 1 | 2015 | 20 | 0.110 |
Why?
| | Aminopeptidases | 2 | 2024 | 21 | 0.110 |
Why?
| | V(D)J Recombination | 1 | 2014 | 8 | 0.110 |
Why?
| | Biomarkers | 3 | 2024 | 4254 | 0.110 |
Why?
| | Complement Activation | 1 | 2017 | 411 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 981 | 0.100 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2015 | 167 | 0.100 |
Why?
| | Adenosine | 2 | 2013 | 254 | 0.100 |
Why?
| | Antiviral Agents | 1 | 2020 | 767 | 0.100 |
Why?
| | Gene Expression | 1 | 2019 | 1487 | 0.100 |
Why?
| | Combined Modality Therapy | 3 | 2023 | 1264 | 0.100 |
Why?
| | Liver Neoplasms | 1 | 2020 | 780 | 0.100 |
Why?
| | Mice, Inbred NOD | 1 | 2015 | 610 | 0.100 |
Why?
| | Perioperative Period | 1 | 2013 | 71 | 0.100 |
Why?
| | Hemoglobins | 1 | 1996 | 383 | 0.100 |
Why?
| | Graft Rejection | 1 | 2017 | 540 | 0.100 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2015 | 339 | 0.100 |
Why?
| | Virulence Factors | 1 | 2015 | 172 | 0.100 |
Why?
| | Antigens | 2 | 2020 | 347 | 0.100 |
Why?
| | Lymphocytes, Null | 1 | 2012 | 3 | 0.100 |
Why?
| | Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 2012 | 27 | 0.100 |
Why?
| | Thymus Gland | 1 | 2014 | 311 | 0.100 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2024 | 928 | 0.100 |
Why?
| | Thymoma | 1 | 2012 | 36 | 0.100 |
Why?
| | Nerve Growth Factors | 1 | 2013 | 78 | 0.100 |
Why?
| | Computational Biology | 1 | 2018 | 680 | 0.090 |
Why?
| | 5'-Nucleotidase | 1 | 2013 | 49 | 0.090 |
Why?
| | Pneumonia, Viral | 1 | 2018 | 382 | 0.090 |
Why?
| | Aspirin | 1 | 1996 | 399 | 0.090 |
Why?
| | Reperfusion | 1 | 2012 | 54 | 0.090 |
Why?
| | Jurkat Cells | 1 | 2012 | 114 | 0.090 |
Why?
| | Intraoperative Complications | 1 | 2013 | 155 | 0.090 |
Why?
| | Adenosine-5'-(N-ethylcarboxamide) | 1 | 2012 | 9 | 0.090 |
Why?
| | Lung | 3 | 2017 | 4108 | 0.090 |
Why?
| | Pancreatic Neoplasms | 1 | 2020 | 918 | 0.090 |
Why?
| | Equilibrative Nucleoside Transporter 1 | 1 | 2012 | 20 | 0.090 |
Why?
| | Intestinal Diseases | 1 | 2012 | 43 | 0.090 |
Why?
| | Lymphocyte Activation | 4 | 2020 | 1126 | 0.090 |
Why?
| | Antigenic Variation | 1 | 2011 | 11 | 0.090 |
Why?
| | Hypoxia-Inducible Factor 1 | 1 | 2012 | 69 | 0.090 |
Why?
| | Moloney murine leukemia virus | 1 | 2011 | 13 | 0.090 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2013 | 198 | 0.090 |
Why?
| | Liver | 1 | 2020 | 1884 | 0.090 |
Why?
| | Mice, Mutant Strains | 1 | 2012 | 299 | 0.090 |
Why?
| | Cell Hypoxia | 1 | 2012 | 247 | 0.090 |
Why?
| | Vaccines, Subunit | 1 | 2011 | 53 | 0.090 |
Why?
| | Hospital Mortality | 1 | 2016 | 1027 | 0.080 |
Why?
| | Perioperative Care | 1 | 2013 | 230 | 0.080 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2012 | 341 | 0.080 |
Why?
| | Nitric Oxide | 1 | 1996 | 897 | 0.080 |
Why?
| | MicroRNAs | 1 | 2017 | 700 | 0.080 |
Why?
| | Viral Envelope Proteins | 1 | 2011 | 98 | 0.080 |
Why?
| | Tumor Suppressor Proteins | 1 | 2013 | 321 | 0.080 |
Why?
| | RNA Interference | 1 | 2012 | 476 | 0.080 |
Why?
| | Gene Expression Profiling | 2 | 2019 | 1782 | 0.080 |
Why?
| | Blotting, Western | 1 | 2013 | 1187 | 0.080 |
Why?
| | Adenocarcinoma | 1 | 2017 | 927 | 0.080 |
Why?
| | Cancer Vaccines | 1 | 2011 | 160 | 0.080 |
Why?
| | Algorithms | 1 | 2018 | 1834 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 479 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1559 | 0.080 |
Why?
| | Purines | 1 | 2011 | 187 | 0.080 |
Why?
| | Sepsis | 1 | 2016 | 640 | 0.080 |
Why?
| | Regional Blood Flow | 1 | 2012 | 512 | 0.080 |
Why?
| | Colitis | 1 | 2012 | 280 | 0.070 |
Why?
| | Diabetic Nephropathies | 1 | 2013 | 314 | 0.070 |
Why?
| | Endothelium, Vascular | 1 | 1996 | 963 | 0.070 |
Why?
| | Female | 13 | 2020 | 77976 | 0.070 |
Why?
| | Cell Differentiation | 2 | 2016 | 2048 | 0.070 |
Why?
| | Intestines | 1 | 2012 | 358 | 0.070 |
Why?
| | Integrin alpha4 | 1 | 2008 | 7 | 0.070 |
Why?
| | Interleukin-1 | 1 | 2012 | 961 | 0.070 |
Why?
| | ErbB Receptors | 2 | 2023 | 627 | 0.070 |
Why?
| | Up-Regulation | 1 | 2011 | 851 | 0.070 |
Why?
| | Mice, Nude | 2 | 2020 | 682 | 0.070 |
Why?
| | Male | 11 | 2020 | 72035 | 0.070 |
Why?
| | Models, Immunological | 1 | 2008 | 100 | 0.070 |
Why?
| | Respiratory Mucosa | 1 | 2011 | 322 | 0.070 |
Why?
| | Membrane Proteins | 2 | 2021 | 1165 | 0.070 |
Why?
| | Gastric Mucosa | 1 | 2007 | 52 | 0.060 |
Why?
| | Gene Knockdown Techniques | 2 | 2018 | 336 | 0.060 |
Why?
| | Phenotype | 2 | 2021 | 3157 | 0.060 |
Why?
| | Virulence | 2 | 2015 | 278 | 0.060 |
Why?
| | Health | 1 | 2007 | 81 | 0.060 |
Why?
| | Salmonella enterica | 1 | 2007 | 59 | 0.060 |
Why?
| | Salmonella Infections | 1 | 2007 | 60 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2008 | 758 | 0.060 |
Why?
| | Immunity | 1 | 2007 | 139 | 0.060 |
Why?
| | Polymerase Chain Reaction | 2 | 2021 | 1054 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 1 | 2012 | 2359 | 0.050 |
Why?
| | B7-1 Antigen | 1 | 2023 | 55 | 0.050 |
Why?
| | B-Lymphocytes | 1 | 2009 | 876 | 0.050 |
Why?
| | Herpesvirus 4, Human | 1 | 2024 | 176 | 0.050 |
Why?
| | Tryptophan Oxygenase | 1 | 2023 | 33 | 0.050 |
Why?
| | Antibodies, Monoclonal | 2 | 2022 | 1519 | 0.050 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2023 | 55 | 0.050 |
Why?
| | Viral Plaque Assay | 1 | 2002 | 29 | 0.050 |
Why?
| | Acrylamides | 1 | 2023 | 70 | 0.050 |
Why?
| | Obesity | 1 | 2016 | 3057 | 0.050 |
Why?
| | Organoids | 1 | 2024 | 141 | 0.050 |
Why?
| | 3T3 Cells | 1 | 2002 | 156 | 0.050 |
Why?
| | Aniline Compounds | 1 | 2023 | 119 | 0.040 |
Why?
| | Kynurenine | 1 | 2023 | 113 | 0.040 |
Why?
| | Smoking | 1 | 2009 | 1468 | 0.040 |
Why?
| | Cell Communication | 2 | 2017 | 324 | 0.040 |
Why?
| | Macrophages | 2 | 2019 | 1510 | 0.040 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2021 | 23 | 0.040 |
Why?
| | Luciferases | 1 | 2021 | 152 | 0.040 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2021 | 42 | 0.040 |
Why?
| | Postoperative Complications | 1 | 2013 | 2916 | 0.040 |
Why?
| | Transcription, Genetic | 2 | 2020 | 1495 | 0.040 |
Why?
| | Cetuximab | 1 | 2021 | 111 | 0.040 |
Why?
| | Glomerulonephritis, Membranoproliferative | 1 | 2020 | 25 | 0.040 |
Why?
| | Major Histocompatibility Complex | 1 | 2021 | 229 | 0.040 |
Why?
| | Receptors, CCR | 1 | 2020 | 6 | 0.040 |
Why?
| | Bacterial Proteins | 1 | 2007 | 954 | 0.040 |
Why?
| | Immunocompetence | 1 | 2000 | 47 | 0.040 |
Why?
| | Platelet Count | 1 | 2020 | 96 | 0.040 |
Why?
| | Basophils | 1 | 2020 | 52 | 0.040 |
Why?
| | Gene Targeting | 1 | 2000 | 82 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 83 | 0.040 |
Why?
| | Tumor Burden | 1 | 2021 | 319 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2019 | 39 | 0.040 |
Why?
| | Suppressor of Cytokine Signaling 1 Protein | 1 | 2019 | 12 | 0.040 |
Why?
| | Mutation | 2 | 2023 | 4085 | 0.040 |
Why?
| | Interferons | 1 | 2021 | 188 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2022 | 462 | 0.040 |
Why?
| | Neoplasms | 2 | 2024 | 2870 | 0.040 |
Why?
| | Chemokine CXCL9 | 1 | 2019 | 38 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2020 | 316 | 0.040 |
Why?
| | Sequence Analysis, DNA | 1 | 2002 | 824 | 0.040 |
Why?
| | Mice, SCID | 1 | 2000 | 369 | 0.040 |
Why?
| | Pyrimidines | 1 | 2023 | 532 | 0.040 |
Why?
| | Transfection | 1 | 2021 | 938 | 0.040 |
Why?
| | Pancreaticoduodenectomy | 1 | 2020 | 135 | 0.040 |
Why?
| | Homeodomain Proteins | 2 | 2013 | 523 | 0.040 |
Why?
| | Postoperative Period | 1 | 2020 | 353 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2020 | 148 | 0.040 |
Why?
| | Indoles | 1 | 2023 | 501 | 0.040 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2019 | 177 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2021 | 744 | 0.040 |
Why?
| | Heterografts | 1 | 2019 | 143 | 0.040 |
Why?
| | Gene Silencing | 1 | 2019 | 205 | 0.030 |
Why?
| | TRPP Cation Channels | 1 | 2018 | 74 | 0.030 |
Why?
| | DNA Repair | 1 | 2020 | 255 | 0.030 |
Why?
| | Lymphocytes | 1 | 2020 | 382 | 0.030 |
Why?
| | RNA Transport | 1 | 2017 | 27 | 0.030 |
Why?
| | Antibodies, Blocking | 1 | 2017 | 37 | 0.030 |
Why?
| | Repressor Proteins | 1 | 2021 | 437 | 0.030 |
Why?
| | Cell Cycle | 1 | 2020 | 596 | 0.030 |
Why?
| | Complement C3d | 1 | 2017 | 67 | 0.030 |
Why?
| | Macaca mulatta | 1 | 2018 | 191 | 0.030 |
Why?
| | Chemoradiotherapy | 1 | 2019 | 237 | 0.030 |
Why?
| | Radiotherapy | 1 | 2018 | 206 | 0.030 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2017 | 86 | 0.030 |
Why?
| | Monocytes | 1 | 2020 | 538 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2019 | 1304 | 0.030 |
Why?
| | Cell Degranulation | 1 | 2016 | 42 | 0.030 |
Why?
| | Arenaviridae Infections | 1 | 2016 | 17 | 0.030 |
Why?
| | Ovalbumin | 1 | 2017 | 190 | 0.030 |
Why?
| | Complement C3 | 1 | 2017 | 191 | 0.030 |
Why?
| | Lectins, C-Type | 1 | 2016 | 62 | 0.030 |
Why?
| | Survival Analysis | 1 | 2020 | 1382 | 0.030 |
Why?
| | Papillomavirus E7 Proteins | 1 | 2016 | 11 | 0.030 |
Why?
| | Granzymes | 1 | 2016 | 49 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2023 | 968 | 0.030 |
Why?
| | Calcimycin | 1 | 1996 | 36 | 0.030 |
Why?
| | Immunoglobulin M | 1 | 2017 | 284 | 0.030 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 1996 | 49 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 431 | 0.030 |
Why?
| | Cyclic GMP | 1 | 1996 | 92 | 0.030 |
Why?
| | Renal Artery | 1 | 1996 | 43 | 0.030 |
Why?
| | B-Cell Activating Factor | 1 | 2015 | 21 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2017 | 415 | 0.030 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 210 | 0.030 |
Why?
| | Neutralization Tests | 1 | 2015 | 76 | 0.030 |
Why?
| | Chemokines | 1 | 2016 | 218 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2020 | 8243 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2015 | 66 | 0.030 |
Why?
| | Cell Survival | 1 | 2018 | 1098 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2021 | 846 | 0.030 |
Why?
| | Acetylcholine | 1 | 1996 | 204 | 0.030 |
Why?
| | Nitric Oxide Synthase | 1 | 1996 | 235 | 0.030 |
Why?
| | Cyclic AMP | 1 | 1996 | 208 | 0.030 |
Why?
| | Stem Cell Niche | 1 | 2015 | 58 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1715 | 0.030 |
Why?
| | Immunoblotting | 1 | 2015 | 300 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2018 | 668 | 0.030 |
Why?
| | Integrin alpha Chains | 1 | 2014 | 22 | 0.030 |
Why?
| | Interleukin-27 | 1 | 2014 | 13 | 0.030 |
Why?
| | Dogs | 1 | 1996 | 437 | 0.030 |
Why?
| | Toll-Like Receptor 3 | 1 | 2014 | 28 | 0.030 |
Why?
| | Femoral Artery | 1 | 1996 | 189 | 0.030 |
Why?
| | Poly I-C | 1 | 2014 | 57 | 0.030 |
Why?
| | Autoimmunity | 1 | 2020 | 924 | 0.030 |
Why?
| | CD11b Antigen | 1 | 2014 | 60 | 0.030 |
Why?
| | California | 1 | 2016 | 469 | 0.030 |
Why?
| | Toll-Like Receptor 7 | 1 | 2014 | 43 | 0.030 |
Why?
| | DNA Primers | 1 | 2015 | 511 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 1996 | 1047 | 0.030 |
Why?
| | Cellular Senescence | 1 | 2016 | 226 | 0.030 |
Why?
| | Cell Movement | 1 | 2018 | 965 | 0.030 |
Why?
| | Bone Marrow | 1 | 2015 | 304 | 0.030 |
Why?
| | Netrin-1 | 1 | 2013 | 15 | 0.020 |
Why?
| | Gene Deletion | 1 | 2015 | 387 | 0.020 |
Why?
| | Imidazoles | 1 | 2014 | 254 | 0.020 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2016 | 267 | 0.020 |
Why?
| | Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2012 | 31 | 0.020 |
Why?
| | Adenosine Deaminase | 1 | 2013 | 43 | 0.020 |
Why?
| | Vasodilation | 1 | 1996 | 522 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2013 | 198 | 0.020 |
Why?
| | Adult | 3 | 2023 | 40262 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 1996 | 824 | 0.020 |
Why?
| | Nucleoside Transport Proteins | 1 | 2012 | 8 | 0.020 |
Why?
| | No-Reflow Phenomenon | 1 | 2012 | 7 | 0.020 |
Why?
| | Dipyridamole | 1 | 2012 | 28 | 0.020 |
Why?
| | Receptors, Purinergic P1 | 1 | 2012 | 30 | 0.020 |
Why?
| | Albuminuria | 1 | 2013 | 187 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2019 | 1313 | 0.020 |
Why?
| | Chimerism | 1 | 2012 | 35 | 0.020 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2012 | 132 | 0.020 |
Why?
| | Apoptosis | 1 | 2020 | 2430 | 0.020 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2012 | 73 | 0.020 |
Why?
| | Membrane Glycoproteins | 1 | 2014 | 496 | 0.020 |
Why?
| | Prognosis | 1 | 2020 | 4278 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 1996 | 2026 | 0.020 |
Why?
| | Gastrointestinal Diseases | 1 | 2013 | 216 | 0.020 |
Why?
| | Antigens, CD | 1 | 2014 | 555 | 0.020 |
Why?
| | Nanoparticles | 1 | 2017 | 519 | 0.020 |
Why?
| | Receptors, Purinergic | 1 | 2011 | 20 | 0.020 |
Why?
| | DNA Methylation | 1 | 2016 | 681 | 0.020 |
Why?
| | Disease Progression | 1 | 2018 | 2840 | 0.020 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2011 | 175 | 0.020 |
Why?
| | Chemotaxis | 1 | 2011 | 122 | 0.020 |
Why?
| | Transcriptome | 1 | 2016 | 1044 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2013 | 1367 | 0.020 |
Why?
| | Alleles | 1 | 2012 | 878 | 0.020 |
Why?
| | Inflammasomes | 1 | 2011 | 146 | 0.020 |
Why?
| | Lipopolysaccharides | 1 | 2013 | 863 | 0.020 |
Why?
| | Fibroblasts | 1 | 2015 | 1032 | 0.020 |
Why?
| | Immunoglobulin Class Switching | 1 | 2009 | 21 | 0.020 |
Why?
| | Phagocytosis | 1 | 2011 | 299 | 0.020 |
Why?
| | Age Factors | 1 | 2016 | 3313 | 0.020 |
Why?
| | Aged | 2 | 2020 | 25850 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2011 | 508 | 0.020 |
Why?
| | Infection Control | 1 | 2009 | 171 | 0.020 |
Why?
| | Epitopes | 1 | 2009 | 485 | 0.020 |
Why?
| | Organ Specificity | 1 | 2007 | 312 | 0.020 |
Why?
| | Myocardial Infarction | 1 | 2013 | 1208 | 0.010 |
Why?
| | Middle Aged | 2 | 2020 | 35762 | 0.010 |
Why?
| | Critical Illness | 1 | 2012 | 889 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2012 | 1497 | 0.010 |
Why?
| | Transcription Factors | 1 | 2012 | 1739 | 0.010 |
Why?
| | Stroke | 1 | 2013 | 1254 | 0.010 |
Why?
| | Vaccines | 1 | 2009 | 389 | 0.010 |
Why?
| | Risk Factors | 1 | 2016 | 10699 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2020 | 17009 | 0.010 |
Why?
| | Vaccination | 1 | 2009 | 1422 | 0.010 |
Why?
|
|
Clambey's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|